Effects of Quetiapine on Ultrastructural Hippocampal and Neurochemical Changes in Patients With Bipolar Disorder: Searching for Antidepressant and Mood Stabilising Neurophysiology

NCT ID: NCT01552837

Last Updated: 2012-03-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-12-31
• Study Completion Date: 2010-12-31

Brief Summary

The aim of the study was to determine the pharmacological induced equivalents of neurogenesis and synaptic sprouting in the hippocampus, localized volume changes, changes in water content and neurochemical changes in the medial temporal regions.

Detailed Description

Quetiapine is an antipsychotic that has mood stabilizing and antidepressant effects (Vieta, 2005). Animal studies showed that the expression of neurotrophins and the subsequent modulation of the neuroplastic processes, including neurogenesis in the hippocampus, play a key role in the mechanism of mood stabilizing (Kim et al., 2004) and antidepressant (Santarelli et al., 2003). Since atypical antipsychotics also have antidepressant and mood stabilizing effect, it is hypothesized that the common mechanism of action in all three pharmacological classes is neurogenesis and synaptic sprouting in the hippocampal region. Thus, the aim of this study was to test this hypothesis.

Quetiapine was associated with antidepressant and mood stabilizing effects in patients with bipolar disorder (Vieta, 2005). The evidence based on animal studies shows that administration of quetiapine attenuates the decrease in levels of brain-derived neurotrophic factor in the hippocampi. This may explain the improved cognitive symptoms in patients with schizophrenia and depression (Luo et al., 2005, Park et al, 2006).

The aim of the study was to determine the pharmacological induced equivalents of neurogenesis and synaptic sprouting in the hippocampus, localized volume changes, changes in water content and neurochemical changes in the medial temporal regions.

Conditions

Bipolar Disorder

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Healthy volunteers

MRI compatible, no present or past DSM-IV diagnosis

Group Type: NO_INTERVENTION

No interventions assigned to this group

patients with Bipolar Disorder

MRI compatible, presence of DSM-IV diagnosis for Bipolar Disorder

Group Type: ACTIVE_COMPARATOR

Seroquel

Intervention Type: DRUG

for 4 weeks, 300 - 800 mg per day in 2 doses

Interventions

Seroquel

for 4 weeks, 300 - 800 mg per day in 2 doses

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• age ranging 18 - 55 years old
• intelligence coefficient (IQ) of minimum 85 as estimated by MWT-B
• MRI compatibility
• for healthy volunteers - no DSM-IV diagnosis
• patients should have had a diagnosis of bipolar disorder in accordance with DSM-IV.

Exclusion Criteria

• substances or alcohol abuse or dependence (except caffeine and nicotine) at enrollment;
• medical conditions that would affect absorption, distribution, metabolism or excretion of study treatment;
• unstable or inadequately treated medical illness (diabetes, angina, pectoris, hypertension);
• diabetes mellitus
• patients who in the opinion of the investigator pose a risk of suicide or danger to self or others,
• patients who known intolerance or lack of response to Quetiapine fumarate,
• patients who use of any of the cytochrome P450 3A4 inhibitors (ketoconazole, itraconazole, nelfinavir, ritonavir, fluvoxamine and saquinavir) in the 14 days preceding enrollment,
• patients who use of any of the cytochrome P450 inducers (phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort and glucocorticoids) in the 14 days preceding enrollment,
• current treatment of Quetiapine or use of mood stabilizer or antidepressant as co-medication throughout the study.
• lack of inform consent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

RWTH Aachen University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Klaus Mathiak, Prof MD

Role: STUDY_DIRECTOR

Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital Aachen

Locations

Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital Aachen

Aachen, , Germany

Countries

Germany

References

Basser PJ, Mattiello J, LeBihan D. Estimation of the effective self-diffusion tensor from the NMR spin echo. J Magn Reson B. 1994 Mar;103(3):247-54. doi: 10.1006/jmrb.1994.1037.

Reference Type: BACKGROUND

PMID: 8019776 (View on PubMed)

Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res. 2005 Nov 23;1063(1):32-9. doi: 10.1016/j.brainres.2005.09.043. Epub 2005 Nov 4.

Reference Type: BACKGROUND

PMID: 16271709 (View on PubMed)

Vieta E. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine. Hum Psychopharmacol. 2005 Jun;20(4):225-36. doi: 10.1002/hup.689.

Reference Type: BACKGROUND

PMID: 15880391 (View on PubMed)

Other Identifiers

2007-000479-40

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

EK 024/07

Identifier Type: OTHER

Identifier Source: secondary_id

07-010

Identifier Type: OTHER

Identifier Source: secondary_id

D1449L00030

Identifier Type: -

Identifier Source: org_study_id